Welcome to our dedicated page for Alzamend Neuro SEC filings (Ticker: ALZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alzamend Neuro, Inc. (ALZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Alzamend Neuro is a clinical-stage biopharmaceutical company whose common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Capital Market under the symbol ALZN, as noted in multiple Form 8-K filings.
Through this page, readers can review Alzamend Neuro’s current reports on Form 8-K, which cover a range of material events. Recent 8-K filings have disclosed unregistered sales of equity securities upon conversion of Series B convertible preferred stock into common stock, Certificates of Elimination for Series A, Series B and Series C convertible preferred stock, audited financial results furnished via press release, and corporate developments such as the passing of a director. These filings also confirm the company’s status as an emerging growth company and list its Nasdaq trading information.
In addition to 8-Ks, investors may consult Alzamend Neuro’s annual report on Form 10-K and other periodic reports, which are referenced in the company’s press releases. These documents typically include details on its clinical-stage pipeline (AL001 and ALZN002), licensing arrangements with the University of South Florida Research Foundation, Inc., risk factors and financial condition.
On Stock Titan, SEC documents are paired with AI-powered summaries that explain the key points of each filing in plain language. Users can quickly see what a particular 8-K, 10-K or other report means for Alzamend Neuro’s capital structure, clinical programs or governance without reading every page. Filings are updated as they appear on EDGAR, and insider or equity-related disclosures, such as unregistered sales of securities, can be reviewed in context with the company’s broader regulatory history.
Alzamend Neuro, Inc. reported the results of its annual stockholder meeting. Stockholders, representing 3,804,741 shares of common stock as of the record date, elected seven directors to serve until the next annual meeting and ratified Haskell & White LLP as the independent auditor for the year ending April 30, 2026.
They also approved, on a non-binding advisory basis, executive compensation and the Company’s 2025 Stock Incentive Plan, as well as equity issuances to directors and executive officers for Nasdaq Listing Rule 5635(c) compliance. Stockholders authorized an amendment to the Certificate of Incorporation to permit a reverse stock split at a ratio between one-for-two and one-for-ten, to be implemented at the board’s discretion any time before April 16, 2027, and approved potential adjournments of the meeting to solicit additional proxies if needed.
Alzamend Neuro, Inc. director Milton C. Ault III, through affiliated entities, reported an indirect open-market purchase of 108,388 shares of common stock at $1.0047 per share on April 14, 2026, executed by Ault Lending, LLC.
After this trade, Ault Lending, LLC held 116,648 common shares. Separate indirect holdings disclosed include 11,068 shares held by Ault Life Sciences, Inc. and 61 shares held by Ault Life Sciences Fund, LLC, with Mr. Ault having voting and investment power over these entities’ positions.
Alzamend Neuro, Inc. reported that Nasdaq has notified the company its stockholders’ equity no longer meets the Nasdaq Capital Market minimum of $2.5 million. Based on its Form 10-Q, stockholders’ equity was about $2.2 million as of January 31, 2026.
The notice does not immediately affect trading, and the stock will continue on Nasdaq under the symbol ALZN. Alzamend has 45 days, until May 4, 2026, to submit a plan to regain compliance and could receive up to September 16, 2026 to demonstrate compliance if Nasdaq accepts the plan. The company is evaluating options but warns there is no assurance its plan will be accepted or that compliance will be restored.
If Alzamend cannot regain compliance or meet other Nasdaq requirements, its common stock could be delisted, though it would have the right to appeal to a Nasdaq Hearings Panel. The company also highlights ongoing risks, including continued losses, negative cash flow, need for additional funding, limited revenue from its core platform, and an evolving business model.
Alzamend Neuro, Inc. reported a net loss of $2.2 million for the quarter and $5.9 million for the nine months ended January 31, 2026, with no product revenue as it advances two CNS drug candidates, AL001 and ALZN002.
Research and development expenses rose sharply to $1.3 million for the quarter and $3.2 million year‑to‑date, mainly from AL001 Phase II work with Massachusetts General Hospital. General and administrative expenses were $0.9 million for the quarter and $2.7 million for nine months, driven by legal fees, including litigation related to an ALZN002 CRO.
Cash was $2.7 million and working capital $1.8 million as of January 31, 2026, after using $5.3 million in operating cash flows and raising $4.0 million from Series C preferred stock. Management states there is “substantial doubt” about the company’s ability to continue as a going concern without additional financing and has launched a $3.0 million at‑the‑market equity program. The company also reports a continuing material weakness in internal control over financial reporting.
Alzamend Neuro, Inc. has filed a prospectus supplement to sell up to $3,000,000 of its common stock in an at-the-market offering through Ascendiant Capital Markets, LLC.
The sales agent will act as an agent or principal and receive a fee equal to 3% of gross proceeds. As of the prospectus supplement date, there were 3,804,741 shares issued and outstanding.
Alzamend Neuro, Inc. entered into an at-the-market sales agreement with Ascendiant Capital Markets to offer up to $3.0 million of its common stock. The shares will be issued from time to time under the company’s existing Form S-3 shelf registration.
Sales will be made through Ascendiant acting as sales agent, using commercially reasonable efforts and within parameters such as share amounts, timing, daily limits, and minimum prices that Alzamend sets. Either party can suspend offers or terminate the agreement by written notice. A legal opinion on the validity of the shares and the full agreement are filed as exhibits.
Alzamend Neuro is asking stockholders to vote at its virtual 2026 annual meeting on April 17, 2026 at 12:00 p.m. Eastern time. Stockholders will elect seven directors, ratify Haskell & White LLP as auditor, and give a non-binding advisory vote on executive compensation.
They are also asked to approve a 2025 Stock Incentive Plan covering 1.6 million shares of common stock and separate equity issuances to directors and executive officers. As of the February 25, 2026 record date, 3,804,741 shares of common stock were outstanding, with a 35% quorum requirement.
Another key proposal would amend the certificate of incorporation to authorize a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-10, at the Board’s discretion any time before April 16, 2027. A final proposal would permit adjournments of the meeting to solicit additional proxies. The Board recommends voting FOR all seven proposals.
Alzamend Neuro is asking stockholders at its April 17, 2026 virtual annual meeting to approve several key governance and capital actions. Proposals include electing seven directors, ratifying Haskell & White LLP as auditor, and a non-binding advisory vote on executive pay.
The company seeks approval of a 2025 Stock Incentive Plan authorizing equity-based awards, and separate approval for equity issuances to directors and executive officers under Nasdaq Listing Rule 5635(c). It is also requesting authority to implement a reverse stock split of common stock at a ratio between one-for-two and one-for-ten any time before April 16, 2027, and to adjourn the meeting if more time is needed to secure votes.
Alzamend Neuro, Inc. reported the passing of board member Andrew H. Woo, M.D., Ph.D., who died on November 14, 2025. Dr. Woo had served on the company’s Board of Directors since its initial public offering in June 2021, contributing medical and scientific expertise to the company’s governance.
Board Chairman William B. Horne praised Dr. Woo as an outstanding director who provided exceptional inspiration and noted he will be deeply missed as both a colleague and a friend. The company extended condolences to his family, friends and all those whose lives he touched.
Alzamend Neuro (ALZN) reported an insider transaction on a Form 4. A director sold 30 shares of common stock on 10/23/2025 at $2.29 per share (transaction code S). Following the sale, the reporting person beneficially owned 25 shares, held directly. The filing was submitted by one reporting person and shows no derivative securities activity.